Investigational drug · Phase 2
HT-4253
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimers Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HT-4253"
First trial start
2026
May 12, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HT-4253", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimers Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "HT-4253" as an intervention, largest first.
- Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 CarriersPivotal-lookingRecruiting
Halia Therapeutics, Inc.Industry
NCT07399171 · 112 participants (planned) · Start May 12, 2026 · Primary completion Feb 2028
Drug: HT-4253 · For: Alzheimers Disease
Sites: Abu Dhabi, United Arab Emirates · 3 sites in all
Halia Therapeutics, Inc.Industry
NCT06537817 · 80 participants · Start Sep 17, 2024 · Primary completion May 12, 2025
Drug: HT-4253; Placebo · For: Normal Healthy Subjects
Sites: Adelaide, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Alzheimers Disease
- TrontinemabRO7126209, RG6102Phase 34 trials
Roche (Genentech) · Alzheimers Disease, Alzheimer's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.